INTRODUCTION
IL-6 and NO that help amplify the immune response and can lead to immunotoxicity. 2, 4, 5 Although the physiological responses to LPS are reasonably well characterized, a thorough understanding of the cellular and biochemical processes by which LPS activates macrophages is generally unknown. However, because the key to homeostasis is the ability to balance the inflammatory process, it is especially critical to understand how multiple factors can modulate the LPS responsiveness of the immune system.
LPS action and extracellular nucleotides
Earlier investigations have noted that many events initiated by LPS are similar to those mediated by guanine-nucleotide binding protein (G-protein) activities (Table 1) . 6, 7 Based on these and other observations, it was postulated that G-proteins were important for LPS action. 6 In support of this hypothesis, a role for G-proteins in endotoxicity was provided by studies demonstrating that LPS stimulates a GTPase activity in murine RAW 264.7 macrophage membranes. 6, 7 Furthermore, during the course of these studies, it was noted that LPS stimulation of the macrophage membrane GTPase activity could be greatly enhanced by ATP and ADP. This observation led to the idea that adenine nucleotides may be involved in LPS action, particularly since macrophages are likely to encounter extracellular ATP and ADP in vivo as these compounds are released from platelets and other cells during inflammation or injury. 8 Extracellular nucleotides can exert their effects through a class of cell surface receptors known as the P2 receptors, which are divided into two subfamilies -P2Y and P2X. [8] [9] [10] [11] Seven P2Y receptors have been identified in mammals, they contain seven-transmembrane segments, and they are associated with G-protein activation. 10 On the other hand, the P2X receptors are a family of ligand-gated, cation-selective ion channels of which seven distinct subunit isoforms have been identified. 8, 11 Macrophages express several different P2Y and P2X receptors, including P2Y 1 , P2Y 2 and P2X 7 , and previous work has implicated both subtypes of receptors in modulating LPS action. 8, 12, 13 For example, it was found that 2-methylthio-ATP (2-MeS-ATP), which is an agonist for multiple P2Y and P2X receptors, inhibited LPS-stimulated release of TNF-a and IL-1b in vivo, and protected mice from LPS-induced death. 7, 8, 10 There is increasing evidence suggesting that P2X 7 may be involved in LPS-mediated macrophage activation. 5, 9, [14] [15] [16] First, pretreatment of RAW 264.7 macrophages with a P2X 7 receptor antagonist, oxidized adenosine 5¢-triphosphate (oATP), inhibits LPS-stimulated NO production and iNOS expression, and attenuates LPS activation of NF-kB and ERK-1/2 (Table 1) . 14 Second, amino acid sequence and structure alignment analyses of P2X 7 identified a region in the C-terminus of the human, rat, and mouse P2X 7 receptor that shares sequence homology with the LPS-binding domain of LPS binding protein and bactericidal permeability increasing protein. 5 Third, peptides to the putative LPS binding region of P2X 7 can bind FITC-labelled-LPS, and when incubated with LPS, these peptides can inhibit LPS-stimulated ERK-1/2 activation and IkB-a degradation. 5 Therefore, the C-terminus of P2X 7 possesses the ability to bind LPS directly and may provide an additional level of LPS recognition and responsiveness besides the wellcharacterized Toll-like receptor 4 (TLR4)/CD14-dependent signaling pathways. [3] [4] [5] 9 Although P2X 7 has been implicated in LPS action, the observation that P2Y receptor ligands (e.g. 2-MeS-ATP) can modulate LPS-induced signaling and mortality, together with the fact that NO production by Mycobacterium tuberculosis infection in P2X 7 knockout mice is inhibited by P2 blockers, supports the idea that multiple P2X and P2Y receptors participate in LPS biology. 7, 9, 16, 17 Thus, the focus of the present study was to test the hypothesis that several purinergic receptors can not only differentially control LPS signaling in various cell types, but may also co-operate in modulating the mammalian inflammatory response and mortality following LPS exposure.
MATERIALS AND METHODS

Cell culture
Murine RAW 264.7 cells and Chinese hamster ovary cells (CHO-K1) were obtained from the American Type Culture Collection. CHO-K1 cells stably transfected with human CD14 (CHO/CD14) or with pcDNA3 (CHO/Neo) were a generous gift from Dr Douglas Golenbock (Boston University, Boston, MA, USA). Cells were maintained in RPMI 1640 medium supplemented with 5% Cosmic Calf Serum (HyClone, Logan, UT, USA), 2 mM L-glutamine, 2 mM sodium pyruvate and 100 U/ml penicillin/streptomycin and were grown at 37°C in a humidified atmosphere containing 5% CO 2 . CHO/Neo and CHO/CD14 cells were maintained in 500 mg/ml G418.
Electrophoretic mobility shift assays
Cells were plated in 10-cm culture plates 2 days before treatment and nuclear extracts were prepared as described previously. 14 The NF-kB Binding Protein Detection System (Gibco, Gaithersburg, MD, USA) was used according to the manufacturer's instructions. End labeling of a double-stranded oligonucleotide containing two consensus NF-kB binding sites (5¢-GATC-CAAGGGGACTTTCCATGGATCCAAGGGGACT TTCCATG-3¢) was performed using [g-32 P]-ATP and T4 polynucleotide kinase. Nuclear extract proteins (5 mg/reaction) were incubated with 10 5 cpm of the labeled oligonucleotide at room temperature for 20 min. The samples were loaded onto pre-run 6% nondenaturing polyacrylamide gels and resolved by electrophoresis. Gels were dried and protein/DNA complexes were visualized by autoradiography.
Measurement of iNOS, NO, TNF-a and IL-1b
RAW 264.7 cells were grown to 80% confluency and treated with LPS (Escherichia coli O111:B4) at the levels and times indicated in the figures. For the NO assays, the medium was removed, and the concentration of NO metabolites in the medium was determined using the Greiss reagent. 14, 15 The levels of iNOS were measured by immunoblotting. 14, 15 For the determination of IL-1b and TNF-a levels, RAW 264.7 macrophages were treated (as detailed in the figure captions) for 4-17 h with 0-1000 ng/ml LPS and the indicated purinergic receptor ligands. Quantikine-M ELISA assays (R&D Systems, Minneapolis, MN, USA) for each cytokine were performed according to the manufacturer's protocol.
Mouse LPS protection studies C57BL/6 mice (2-3 months old, 16-24 g) were isoflurane-anesthetized and injected with 0 or 900 mg LPS (E. coli 0111:B4) followed within 1 min by a contralateral retro-oribital injection of either saline alone or 1 mg of the specified purinergic receptor ligand; all compounds were injected using a saline vehicle. The data are reported as the percentage of animals surviving at 24 h or 48 h. 
RESULTS AND DISCUSSION
P2X 7 receptor involvement in LPS action
Because previous studies have implicated a role for the purinergic receptor P2X 7 in the control of macrophage responsiveness to LPS (Table 1) , we evaluated the ability of a P2X 7 receptor agonist (BzATP) and antagonist (oATP) to regulate LPS-induced mediator production and signaling activities. As seen in Figure 1A , treatment of murine RAW 264.7 macrophages with LPS for 17 h leads to a measurable increase in immunodetectable IL-1b released into the medium, whereas treatment of these cells with LPS for only 6 h results in an undetectable level of IL-1b in the cell culture media. However, when the cells are treated with LPS for 6 h but with the addition of BzATP for the last hour of the incubation, one now sees a substantial increase in IL-1b release. This result does not appear attributable to BzATP alone because there is no detectable release of IL-1b from these cells even after an 18 h incubation with 150 mM BzATP alone (data not shown). A similar response was observed with regard to iNOS expression ( Fig. 1B) , i.e. co-treatment of RAW 264.7 macrophages with LPS and BzATP led to an increase in the expression of iNOS when compared to LPS alone. These data suggest that P2X 7 can exert multiple levels of control over LPS-initiated mechanisms of mediator production.
As an alternative approach to assessing the involvement of P2X 7 in LPS action, the P2X 7 antagonist, Purinergic receptor regulation of LPS-induced signaling and pathophysiology 259 Fig. 1 . Effect of the P2X 7 receptor agonist (BzATP) and antagonist (oATP) on LPS-induced mediator production. (A) Subconfluent murine RAW 264.7 macrophages were treated for the indicated times with either 1 mg/ml of LPS, 150 mM BzATP, or LPS plus BzATP (where BzATP was present for only the last hour of incubation). The medium was then removed and the total levels of IL-1b (processed and unprocessed) were measured by ELISA as described in Materials and Methods. Note: no detectable IL-1b release was observed when the cells were treated for up to 18 h with 150 mM BzATP alone (data not shown). The data are presented as the average of duplicate measurements (± range). Similar results were obtained in two independent experiments. *P < 0.05 when compared to the LPS alone (6 h) treatment group using an unpaired onetailed Student's t-test assuming equal variances. (B) Subconfluent murine RAW 264.7 macrophages were treated for 20 h with the indicated doses of LPS or 150 mM BzATP, or LPS plus BzATP. The cells were lysed and iNOS levels were assessed by immunoblotting as detailed in Materials and Methods. Similar results were obtained in two independent experiments. (C,D) Subconfluent murine RAW 264.7 macrophages were treated for 2 h with 250 mM oATP, the cells were then washed, and subsequently incubated with the indicated concentrations of LPS for either 4 h (C) or 20 h (D). The medium was removed and the levels of TNF-a were assessed by ELISA (C) or NO metabolites were measured using the Greiss reagent (D). Data are shown as the average of triplicate measurements (± SD), and similar results were observed in at least two independent experiments. **P < 0.002 when compared to the group not treated with oATP at each dose of LPS using an unpaired Student's t-test and assuming equal variances. D C B A oATP, was used to block the activity of the P2X 7 receptor in RAW 264.7 cells (Fig. 1C,D) . In these experiments, we observed that pre-treatment of the cells with oATP blocked the capacity of LPS to induce the production of both TNF-a and NO. These data further support the concept that P2X 7 receptor function is critical for maximal macrophage responsiveness to LPS.
Given that the aforementioned pharmacological data suggest that P2X 7 receptor action can affect LPSinduced mediator production, it was of interest to establish the molecular mechanisms involved in the interaction between the P2X 7 receptor and LPS-dependent systems. To this end, we first examined the influence of P2X 7 receptor status on the activation of the transcription factor NF-kB, which is known to be central to many LPS initiated responses. 4, 9, 16 In addition, to explore the potential linkage of P2X 7 receptor action with LPS-dependent systems, CHO cells that naturally express P2X 7 were transfected with or without the LPSbinding molecule CD14 and were then analyzed for their capacity to exhibit NF-kB activation following exposure to LPS or the P2X 7 -selective ligand BzATP. As shown in Figure 2A , CD14 expression enhanced the capacity of LPS to activate NF-kB DNA binding activity in CHO cells. Unexpectedly, CHO cells that do not express CD14 respond poorly to BzATP with regard to NF-kB activation, even though the cells express the P2X 7 receptor and can respond to BzATP with respect to ERK-1/2 activation (data not shown). However, CD14 expression renders the CHO cells sensitive to BzATP with regard to the activation of NF-kB DNA binding activity. These results did not appear to be the result of LPS contamination of the BzATP (data not shown), and thus suggest a regulatory connection between P2X 7 receptor function and the LPS sensitivity of the cell.
Additional evidence supporting P2X 7 involvement in LPS signaling was obtained using mutant RAW 264.7 macrophages that were selected to be hyporesponsive to the P2X 7 receptor ligand BzATP (Table 1) . 18 These cells contain a mutation in the P2X 7 receptor transmembrane domain (S342F) that inactivates the receptor. As shown in Figure 2B , these cells exhibit an attenuated response to LPS with respect to NO production, suggesting that the P2X 7 receptor can cross-talk with the LPS-dependent pathways necessary for mediator production in RAW macrophages.
Purinergic receptor regulation of LPS-induced mortality in mice
Altogether, the above data support the hypothesis that the P2X 7 receptor is involved in LPS action.
However, previous findings have shown that 2-MeS-ATP, which is an agonist for the P2X 7 receptor and would be expected to exacerbate several LPS-induced activities, actually protects mice from LPS-induced 260 Guerra, Fisette, Pfeiffer et al. Fig. 2 . Influence of P2X 7 receptor status on the activation of the transcription factor NF-kB and LPS-induced NO production. (A) Subconfluent CHO cells that naturally express P2X 7 were transfected with or without the LPS-binding molecule CD14 and were then analyzed for their capacity to exhibit NF-kB activation following exposure for 1 h to either 1 mg/ml LPS or 300 mM BzATP and compared to RAW cells. The cells were then lysed, nuclear extracts were prepared and NF-kB DNA binding activity was measured using an electrophoretic mobility shift assay as detailed in Materials and Methods. (B) Subconfluent mutant RAW 264.7 macrophages that are hyporesponsive to the P2X 7 receptor ligand BzATP, variant RAW and contain a mutation in the P2X 7 receptor transmembrane domain (S342F) that inactivates the receptor were treated with the indicated concentrations of LPS for 24 h, the medium was removed and assayed for NO metabolites as described in Materials and Methods. Data are shown as the average of triplicate measurements (± SEM), and similar results were observed in at least two independent experiments. For comparison, with the 1 m g/ml LPS treatment groups, the level of NO production by the RAW 264.7 cells expressing the mutant P2X 7 receptor was different from the wild-type cells at the P < 0.002 level (indicated by **) when evaluated using an unpaired Student's t-test and assuming equal variances. A B death. 7 This observation may be explained by the fact that 2-MeS-ATP is not only a ligand for the P2X 7 receptor, but it is also an agonist for other P2X and P2Y receptors. 10, 11 Accordingly, 2-MeS-ATP may initiate an interaction between purinergic receptor systems and/or lead to their selective down-regulation. Thus, because the complex events required for survival from an LPS challenge involve the interaction between multiple purinergic receptor classes, we elected to examine selectively the contribution of the P2X 7 receptor to the nucleotide-induced survival of animals challenged with a lethal dose of LPS.
In these studies, C57BL/6 mice were challenged with LPS followed by treatment with ligands specific to various purinergic receptor classes. As shown in Figure 3A , the administration of the P2X 7 receptor agonist, BzATP, did not protect mice from a lethal challenge with LPS. On the other hand, 2-MeS-ATP and 2-Cl-ATP, which can both interact with multiple P2X and P2Y receptors 10, 11 (also Guerra et al., manuscript in preparation), were able to block LPS-induced mortality in mice. In addition, Figure 3B whereas previous studies have shown that low doses of 2-MeS-ATP (0.013-0.13 mg/mouse) are less active in this regard. 7 Furthermore, the protective effect of 2-Cl-ATP measured 48 h after LPS exposure is biphasic in its dose-dependent behavior, i.e. higher (1 mg/mouse) and lower (0.01 mg/mouse) doses of 2-Cl-ATP are less efficacious when compared to a 0.1 mg/mouse dose of 2-Cl-ATP. These dose-dependent differences between 2-Cl-ATP and 2-MeS-ATP are not likely a result of molecular weight variations between the two compounds (which differ by only 2%), but may be attributable to the powerful suppressive and stimulatory effects high doses of 2-Cl-ATP may exert on multiple cardiovascular and respiratory activities, which would hamper the animal's ability to combat the already debilitating circumstances associated with endotoxic shock. 3, 8, 10, 19 
Model of purinergic receptor function on LPS action
Based on the results presented here and in previous reports, a working model for the molecular mechanisms whereby various purinergic receptor classes modulate LPS action is presented in Figure 4 . In this model, LPS initiates mediator production through CD14/MD2/ TLR4-dependent pathways as well as through CD14/P2X 7 -dependent pathways (which would be expected to be amplified by the presence of extracellular nucleotides at the inflammatory site). Because P2X 7 is known to possess an LPS/lipid binding domain, one explanation for the link between CD14 and P2X 7 is that CD14 facilitates P2X 7 trafficking or signaling by providing the receptor access to membrane-associated proteins or lipids critical for receptor function. In addition, agonists of the P2X 7 receptor serve to potentiate certain macrophage responses to LPS, whereas antagonists of the P2X 7 receptor can function to attenuate these responses. One mechanism by which this cross-talk between P2X 7 -and LPS-dependent pathways occurs involves the regulation of the DNA binding activity of NF-kB, which provides a nexus for the control of inflammatory mediator production. Furthermore, ligands that can interact with both P2X and P2Y receptors may exert protective effects in vivo by virtue of their ability to downregulate purinergic receptors and/or their associated intracellular signaling effector systems. These events could alter the purinergic receptor status and responsiveness of the cell, thereby contributing to a change in its capacity to produce inflammatory mediators. In addition, such dual-specificity ligands may alter monocyte/macrophage viability and differentiation, thereby attenuating the capacity of these cells to produce certain mediators and affect the survival of the animal. 9,10,19
CONCLUSIONS
Although the action of the P2X 7 receptor is important for macrophage responsiveness to LPS, the protective effects of ligands that bind to both P2X and P2Y receptors likely reflects the interplay of various cell types and purinergic receptor activities, leading to an integrated balance between complex and disparate immunological events.
